Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$313,944

Cost of revenue 169,266 (7,673)(b)(d)(e) 161,593

Gross profit 144,678 7,673 152,351

Gross margin 46% 49%

Operating expenses:

Research and development 24,119 (2,224)(b)(d) 21,895

Selling, general and

administrative 146,765 (57,528)(b)(c)(d) 89,237

Total operating expenses 170,884 (59,752) 111,132

Operating income (loss) (26,206) 67,425 41,219

Interest and other income

(expense), net (20,518) 13,663 (b)(f)(h) (6,855)

Income tax (benefit)

provision 3,205 6,798 (i) 10,003

Equity earnings of

unconsolidated

entities, net of tax 1,560 224 (b) 1,784

Net (loss) income $(48,369) $74,514 $26,145

Preferred stock dividends $- $-

Net (loss) income

available to common

stockholders - basic $(48,369) $26,145

Net (loss) income per

common share

Basic $(1.06) $0.57

Diluted $(1.06)(j) $0.55 (l)

Weighted average common shares

- basic 45,565 45,559

Weighted average common shares

- diluted 45,565 (j) 47,361 (l)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash charges,

including amortization expense and stock-based compensation expense, (ii)

non-recurring charges and income, and (iii) certain other charges and


'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... , , , , , ... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or ... and medical nutrients addressing a variety of diseases and ... flagship Xin Aoxing,Oleanolic Acid ("Xin Aoxing") Capsules for the ...
... , , ORLANDO, Fla., Dec. ... GNLK) a leading consumer genomics and biotechnology company ( www.genelinkbio.com ... Macdonald as its interim Chief Executive Officer, effective December 28, ... leader with more than 25 years of experience building high ...
... , , , , , , , , ... ( SVA),a leading provider of biopharmaceutical products in China, announced today,that ... (SFDA) to commence a human clinical trial for its vaccine,against human ... This is the first clinical trial application for HFMD vaccine,submitted in ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai 2Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 4Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... a new professorship in tissue engineering to promote ... Engineering and the Marine Biological Laboratory, supported by ... Eugene Bell Foundation., The Eugene Bell Professorship in ... Molecular Engineering. That endowed chair holder also will ... Bell Center for Regenerative Biology and Tissue Engineering, ...
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... Oct. 17, 2011 Dr. Randal Halfmann, a ... of 10 investigators selected for the first National Institutes ... new program allows creative early-career scientists to leapfrog the ... independent investigations. The charter group of awardees will share ...
... Oct. 17, 2011 Aware, Inc. (Nasdaq: ... software, today announced the development of the Next-Generation Universal ... agencies of the U.S. Department of Justice. Universal ABS ... BioComponents™ product family; a flexible, modular, COTS software framework ...
... Ga. Nearly all active people suffer ankle sprains at ... Georgia study suggests that the different ways people move their ... In the past, sports medicine therapists prescribed strengthening and ... The study by UGA kinesiology researchers, published in the early ...
Cached Biology News:UT Southwestern biochemist receives new NIH Early Independence Award 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 3Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 4UGA study suggests key to avoiding ankle re-injury may be in the hips and knees 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... Sight DS-L2 imaging controller is a successor ... and allows users to comfortably observe, record ... controller features an 8.4 inch LCD (XGA) ... of Nikon cameras including the DS-Fi1 , ...
... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: